Leatt Corp (LEAT) Stock Price & Analysis
Leatt Corp (LEAT) rose 0.08% to USD 12.91 as of July 25, 2026 at 07:58 UTC, according to Nexqual real-time market data.
LEAT last closed at USD 12.9; the session ranged USD 12.9–12.91 on volume of 400 shares. Market capitalization is $80.47M, with a 52-week range of USD 8.31–14.5 (OQB). Source: Nexqual, July 25, 2026 at 07:58 UTC.
Key Statistics (as of July 25, 2026 at 07:58 UTC)
| Price | USD 12.91 |
|---|---|
| Change | ▲ 0.08% (up) |
| Previous Close | USD 12.9 |
| Open | USD 12.9 |
| Day Range | USD 12.9 – 12.91 |
| 52-Week Range | USD 8.31 – 14.5 |
| Volume | 400 shares |
| Market Cap | $80.47M |
| Exchange | OQB |
Technical Analysis (LEAT)
Nexqual's technical model rates LEAT "BUY" based on 5 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 07:58 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 70.38 (overbought) |
| vs SMA50 | Above (USD 12.18) |
| MACD | 0.24 (positive) |
Analyst Ratings (LEAT)
Wall Street analysts rate LEAT "None", per Nexqual as of July 25, 2026 at 07:58 UTC.
| Consensus Rating | None |
|---|
Earnings (LEAT)
| Next Earnings Date | 2026-08-06 |
|---|
Source: Nexqual, July 25, 2026 at 07:58 UTC.
Financials & Fundamentals (LEAT)
| Total Revenue | $66.05M |
|---|---|
| Revenue Growth (YoY) | +26.90% |
| Gross Margin | +44.02% |
| Operating Margin | +11.88% |
| Profit Margin | +5.92% |
| ROE | +9.37% |
| Debt / Equity | 1.83 |
| Current Ratio | 8.2 |
| Total Cash | $17.01M |
| Total Debt | $803,893 |
| Free Cash Flow | $3.16M |
Source: Nexqual, July 25, 2026 at 07:58 UTC.
Financial Health Score (LEAT)
Nexqual rates Leatt Corp's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 07:58 UTC.
| Growth | Strong — Revenue +27% YoY (latest Q) |
|---|---|
| Profitability | Strong — Gross margin 44%, operating 12% |
| Balance Sheet | Strong — $17M cash, no debt |
| Cash Flow | Mixed — FCF $3M, slim 4.8% margin |
| Efficiency | Mixed — ROE 9%, ROA 6.8% |
Ownership (LEAT)
| Insider Ownership | +45.65% |
|---|---|
| Institutional Ownership | +4.95% |
| Shares Outstanding | 6.23M |
| Float | 3.87M |
Source: Nexqual, July 25, 2026 at 07:58 UTC.
Leadership (LEAT)
Leatt Corp is led by Sean MacDonald C.A., CA (SA) (age 48), CEO, CFO, President & Director, per Nexqual as of July 25, 2026 at 07:58 UTC.
| CEO, CFO, President & Director | Sean MacDonald C.A., CA (SA) (age 48) |
|---|---|
| Founder, Chairman and Research & Development Consultant | Christopher James Leatt ChB, MB (age 57) |
Major Backers & Investors (LEAT)
Notable institutional backers of Leatt Corp include Segall Bryant & Hamill Fundamental International Small Cap Fund, Wynnefield Capital Management LLC, according to Nexqual as of July 25, 2026 at 07:58 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Segall Bryant & Hamill Fundamental International Small Cap Fund | 0.93% |
| Wynnefield Capital Management LLC | 0.16% |
Source: Nexqual, July 25, 2026 at 07:58 UTC.
From Leatt Corp's Latest SEC 10-K Filing (filed 2026-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- FDA and MHRA registration allow us to take these products directly to market as medical devices for patients (not just athletes) recuperating from injuries, surgery, muscle tears or strains, dislocations, breaks or fractures.
- Both our patents and licensed patented technology allows us to provide a product that cannot easily be duplicated by our competitors.
- While such manufacturing arrangements pose a risk to our ability to safeguard our proprietary technologies and may lead to increased costs, as discussed under the "Risk Factors" heading in this report, we expect that the increase in expected sales volumes will contribute to a lower production cost per unit and that this will translate to better margins for our distributors and retailers. •   Research, Development, Certification and Marketing Capabilities .
Partnerships
- De Villiers shares of preferred stock, we entered into a Settlement Agreement with them, pursuant to which they agreed to release us from any and all liability arising out of or related to our failure to satisfy our prior obligation to them, and we issued 16,800,000 shares of our common stock and 2,400,000 shares of our Series A Preferred Stock to Dr.
- Jarrett in accordance with the agreement, but we did not issue any preferred shares to Dr.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TBTC | Table Trac, Inc. | USD 4.5 | ▲ 2.27% |
| GLXZ | Galaxy Gaming, Inc. | USD 1.64 | ▼ 1.2% |
| FTLF | FitLife Brands, Inc. | USD 10.25 | ▼ 0.19% |
| WFCF | Where Food Comes From, Inc. | USD 12.49 | ▲ 3.14% |
| PRKA | Parks! America, Inc. | USD 39 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:58 UTC. This page is informational and not investment advice.